Abstract:Multiple myeloma (MM) is a plasma cell malignancy preliminary localized in the bone marrow and characterized by its capacity to disseminate. IL-6 and IGF-1 have been shown to mediate proliferative and anti-apoptotic signals in plasmocytes. However, in primary plasma-cell leukemia (PCL) and in end-stage aggressive extramedullar disease, the cytokine requirement for both effects may be not mandatory. This suggests that constitutive activation of signaling pathways occurs. One of the signaling pathways whose deregulation may play an oncogenic role in MM is the phosphatidylinositol 3-kinase (PI 3-K) pathway. In human growth factor-independent MM cell lines OPM2 and RPMI8226, we show that the PI 3-K inhibitors LY294002 and Wortmannin strongly inhibited cell proliferation, whereas inhibition of the mammalian Target Of Rapamycin (mTOR)/P70-S6-kinase (P70S6K) pathway with rapamycin or of the Mitogen-Activated Protein Kinase (MAPK) pathway with PD98059 had minimal effect on proliferation. In both cell lines, constitutive activation of the PI 3-K/Akt/FKHRL-1, mTOR/P70S6K and MAPK pathways was detected. LY294002 inhibited phosphorylation of Akt, FKHRL-1 and P70S6K but had no effect on ERK1/2 phosphorylation, indicating that the PI 3-K and MAPK pathways are independent. IGF-1 but not IL-6 increased phosphorylation of Akt, FKHRL-1 and P70S6K. Purified plasmocytes from four patients with MM and two patients with primary PCL were studied. In three of them including the two patients with PCL, constitutive phosphorylation of Akt, FKHRL-1 and P70S6K was present, inhibited by LY294002 and enhanced by IGF-1. In these patients with constitutive Akt activation, normal PTEN expression was detected. PI 3-K inhibition induced caspase-dependent apoptosis as confirmed by inhibition with the large spectrum caspase inhibitor Z-VAD-FMK and cleavage of pro-caspase-3. Both cell lines spontaneously expressed Skp2 and cyclin D1 proteins at high levels but no p27Kip1 protein. In the presence of LY294002, cell-cycle arrest in G0/G1 was observed, p27Kip1 protein expression was up-regulated whereas the expression of both Skp2 and cyclin D1 dramatically diminished. PI 3-K-dependent GSK-3α/β constitutive phosphorylation was also detected in OPM2 cells that may contribute to high cyclin D1 expression. Overall, our results suggest that PI 3-K has a major role in the control of proliferation and apoptosis of growth factor-independent MM cell lines. Most of the biological effects of PI 3-K activation in these cell lines may be mediated by the opposite modulation of p27Kip1 and Skp2 protein expression. Moreover, constitutive activation of this pathway is a frequent event in the biology of MM in vivo and may be more frequently observed in PCL.

A comprehensive review of the PTEN/PI3K/Akt axis in multiple myeloma: From molecular interactions to potential therapeutic targets

Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma.

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma

Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions

PI3K/AKT signaling pathway and cancer: an updated review

Multiple myeloma: signaling pathways and targeted therapy

Targeting PI3K in cancer: mechanisms and advances in clinical trials

The PTEN–PI3K Axis in Cancer

Targeting PI3K/Akt signal transduction for cancer therapy

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

Targeting the PI3K pathway in cancer: are we making headway?

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy

The PTEN–PI3K pathway: of feedbacks and cross-talks

New emerging targets in osteosarcoma therapy: PTEN and PI3K/Akt crosstalk in carcinogenesis

PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications

The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances

Development of PI3K inhibitors: Advances in clinical trials and new strategies (Review)